创新成果的落地，离不开公司全方位的战略支撑。振东制药始终将研发创新作为核心战略，2024年建成 并落地上海新药创制中心，聚焦肿瘤、皮科、消化、泌尿等优势治疗领域，构建"创新药+仿制药+中 药"的多元化产品矩阵。目前，公司在创新药领域多点开花，肾上腺素鼻喷雾、星蒌承气颗粒等多个项 目稳步推进，形成了多赛道协同发展的良好格局。 以创新为帆，以治理为舵，振东制药正在医药行业高质量发展的浪潮中稳步前行。未来，随着阴道用乳 杆菌二联活菌胶囊等创新产品逐步落地，以及多领域研发管线的持续推进，公司将进一步巩固核心竞争 力，为患者提供更多高质量治疗选择，在实现自身高质量发展的同时，为投资者与社会创造更大价值。 从研发进程来看，该项目历经多年技术攻坚，完成了系统的临床前研究与Ⅲ期临床试验，数据显示其治 愈率显著优于对照组，且安全性表现优异，为上市获批奠定了坚实基础。去年8月，该项目Pre-NDA申 请已获CDE审理，此次NDA受理标志着产品正式迈入上市审评关键阶段，距离服务患者更近一步。这 一进展不仅是振东制药在妇科创新药领域的重大突破，更填补了国内天然、安全妇科治疗方案的市场空 白，契合女性健康消费升级趋势。 从市场前景来看 ...

Core Viewpoint - The company, Zhendong Pharmaceutical, has announced that its research and development of the traditional Chinese medicine Class 1 new drug, Xinglou Chengqi Granules, is currently undergoing Phase IIa clinical trials, with the first subject successfully enrolled and administered recently [1] Group 1: Drug Development - The drug is indicated for phlegm clearance and is intended for use in the acute phase of ischemic stroke with phlegm-heat obstructing the channels, presenting symptoms such as hemiplegia, unilateral numbness, speech difficulties, dizziness, and constipation [1] - The clinical trial aims to evaluate the efficacy and safety of Xinglou Chengqi Granules in treating the specified conditions associated with ischemic stroke [1]

Core Viewpoint - Zhendong Pharmaceutical (300158.SZ) has announced that its research and development of the traditional Chinese medicine Class 1 new drug, Xinglou Chengqi Granules, is currently undergoing Phase IIa clinical trials, with the first subject successfully enrolled for treatment recently [1] Group 1 - The drug is indicated for phlegm-dispelling and bowel-clearing, specifically for acute ischemic stroke with phlegm-heat obstructing the bowels, presenting symptoms such as hemiplegia, unilateral numbness, speech difficulties, dizziness, constipation, chest tightness with phlegm, abdominal pain and bloating, nausea, dry mouth with bitter taste, red tongue with yellow greasy coating, and slippery pulse [1]